

Jul 10, 2024

C Lentivirus production and transduction

DOI

dx.doi.org/10.17504/protocols.io.bp2l69jj1lqe/v1

Shiyi Wang¹

¹Duke University

ASAP Collaborative Rese...



Shiyi Wang

Duke University

OPEN ACCESS



DOI: dx.doi.org/10.17504/protocols.io.bp2l69jj1lqe/v1

Document Citation: Shiyi Wang 2024. Lentivirus production and transduction. protocols.io

https://dx.doi.org/10.17504/protocols.io.bp2l69jj1lqe/v1

License: This is an open access document distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Created: May 23, 2023

Last Modified: July 10, 2024

Document Integer ID: 82324

Keywords: ASAPCRN

Funders Acknowledgement: **Aligning Science Across** Parkinson's (ASAP) initiative Grant ID: ASAP-020607



Disclaimer

DISCLAIMER - FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

Abstract

Lentivirus production and transduction



- 1. Lentiviruses containing shRNA targeting vectors were produced to test the knockdown efficiency of shRNA constructs in cultured primary astrocytes or to bulk transduce neurons with shRNA and GFP.
- 2. To produce lentivirus, HEK293T cells were transfected with a pLKO.1 shRNA Puro targeting plasmid (for astrocyte transduction), an envelope plasmid (VSVG), and a packaging plasmid (dR8.91) using X-tremeGENE (Roche).
- 3. One day after transfection, the media was replaced with AGM (for astrocyte transduction), and media containing lentivirus was collected on days 2 and 3 post-transfection.
- 4. To assess the knockdown efficiency of shRNAs in astrocytes, rat primary astrocytes at DIV 7 were plated in 6-well dishes in 2 ml of AGM.
- 5. On DIV 8, 1 ml of AGM was removed, and 500 µl of fresh AGM was added along with 500 µl of lentivirus-containing media and 1 µg/ml polybrene.
- 6. Cultured astrocytes were treated with puromycin (1 μg/ml) from DIV 10-15 to select for transduced cells.
- 7. Cultured astrocytes were lysed at DIV 15 for protein extraction and Western blot analysis.